Recombinant Human ADAMTS19, N-His

Description of Recombinant Human ADAMTS19, N-His

Introduction

Recombinant Human ADAMTS19 is a protein that plays a crucial role in various physiological processes, including extracellular matrix (ECM) organization, tissue development, and inflammation. This protein belongs to the ADAMTS (A Disintegrin And Metalloproteinase with Thrombospondin motifs) family, which consists of 19 members. ADAMTS19 is a secreted protein that is produced by recombinant technology and has been extensively studied for its structure, activity, and potential applications.

Structure of Recombinant Human ADAMTS19

Recombinant Human ADAMTS19 is a 1,656 amino acid protein with a molecular weight of approximately 190 kDa. It is composed of multiple domains, including a signal peptide, a propeptide, a metalloproteinase domain, a disintegrin-like domain, a thrombospondin type 1 motif, a cysteine-rich domain, a spacer domain, and a C-terminal domain. These domains are essential for the proper functioning of ADAMTS19.

The metalloproteinase domain of ADAMTS19 contains a zinc-binding motif, which is responsible for its proteolytic activity. This domain is highly conserved among all members of the ADAMTS family and is crucial for ECM degradation and remodeling. The disintegrin-like domain of ADAMTS19 is involved in cell adhesion and signaling, while the thrombospondin type 1 motif is responsible for protein-protein interactions. The cysteine-rich domain is involved in protein folding and stability, and the spacer domain acts as a linker between the different domains.

Activity of Recombinant Human ADAMTS19

Recombinant Human ADAMTS19 is a proteolytic enzyme that is involved in the degradation and remodeling of the ECM. It is known to cleave various ECM proteins, including aggrecan, versican, and fibronectin. This proteolytic activity is crucial for tissue development, wound healing, and inflammation.

In addition to its proteolytic activity, ADAMTS19 also has anti-angiogenic properties. It inhibits the formation of new blood vessels by cleaving the vascular endothelial growth factor (VEGF) receptor 2. This activity is essential for controlling excessive angiogenesis, which can lead to various diseases, such as cancer and retinopathy.

Applications of Recombinant Human ADAMTS19

Recombinant Human ADAMTS19 has various potential applications in the field of medicine and biotechnology. Its proteolytic activity and anti-angiogenic properties make it a promising candidate for the treatment of various diseases.

One potential application of ADAMTS19 is in tissue engineering and regenerative medicine. Its ability to degrade and remodel the ECM can be utilized to promote tissue repair and regeneration. It can also be used in combination with other growth factors and biomaterials to enhance tissue regeneration.

Another potential application of ADAMTS19 is in the treatment of inflammatory diseases. Its proteolytic activity can help in reducing inflammation by degrading inflammatory mediators and ECM proteins that contribute to the inflammatory response. This can be beneficial in conditions such as rheumatoid arthritis and inflammatory bowel disease.

Furthermore, ADAMTS19 can also be used as a diagnostic and prognostic marker in various diseases. Its expression levels have been found to be altered in certain cancers and cardiovascular diseases, making it a potential biomarker for early detection and monitoring of these diseases.

Conclusion

In conclusion, Recombinant Human ADAMTS19 is a multi-domain protein with proteolytic and anti-angiogenic activities. Its structure and function have been extensively studied, and it has shown promising potential in various applications, including tissue engineering, inflammation, and disease diagnosis. Further research and development of ADAMTS19 may lead to the development of novel therapies for various diseases and contribute to the advancement of biotechnology.